MicroPort CardioFlow shifts to profit, revenue up on TAVI expansion

MicroPort CardioFlow Medtech Corporation reported an operating profit of 3.817 million yuan for the six months ended June 30, 2025, a substantial improvement from a loss of 28.480 million yuan in the same period of 2024. Revenue increased by 2.7% to 229.103 million yuan, primarily driven by overseas expansion of TAVI products and commercialization of LAAC systems. This was achieved despite a 38.1% reduction in R&D costs to 51.407 million yuan and a 9.0% decrease in selling and distribution costs to 79.309 million yuan.

The company maintained its leading position in the China TAVI market with over 2,100 implantations and expanded its TAVI products to 23 countries, achieving a 235.3% increase in overseas revenue. The AnchorMan LAAC System received CE Mark approval and saw significant commercial implantations in the domestic market and successful launches in Poland, Hong Kong, and Macau.

Key strategic initiatives include deepening multi-level hospital coverage, enhancing patient discovery and referral, and building an academic brand. The acquisition of the remaining 49% equity interest in MP CardioAdvent was completed in July 2025, making it a wholly-owned subsidiary. The company aims to achieve full utilization of Global Offering proceeds by the end of 2025.